Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery - PubMed (original) (raw)
Review
Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery
Ronne Wee Yeh Yeo et al. Adv Drug Deliv Rev. 2013 Mar.
Abstract
Advances in biomedical research have generated an unprecedented number of potential targets for therapeutic intervention to treat disease or delay disease progression. Unfortunately, many of these targets are not druggable as they are intracellular, present in many cell types, poorly soluble or rapidly inactivated. Although synthetic drug vehicles have successfully circumvented many of these problems, natural particulates such as exosomes that intrinsically possess many attributes of a drug delivery vehicle are highly attractive as potentially better alternatives. Of the cell types known to produce exosomes, the readily available proliferative, immunosuppressive and clinically tested human mesenchymal stem cell (MSC) is the most prolific producer. Its exosomes are therapeutic in animal model of disease and exhibit immunosuppressive activity. The quality and quantity of exosome production is not compromised by immortalization to create a permanent MSC cell line. Therefore, MSC is well suited for mass production of exosomes that are ideal for drug delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
- Exosomes for drug delivery - a novel application for the mesenchymal stem cell.
Lai RC, Yeo RW, Tan KH, Lim SK. Lai RC, et al. Biotechnol Adv. 2013 Sep-Oct;31(5):543-51. doi: 10.1016/j.biotechadv.2012.08.008. Epub 2012 Aug 25. Biotechnol Adv. 2013. PMID: 22959595 Review. - Mesenchymal stem cell exosome ameliorates reperfusion injury through proteomic complementation.
Lai RC, Yeo RW, Tan KH, Lim SK. Lai RC, et al. Regen Med. 2013 Mar;8(2):197-209. doi: 10.2217/rme.13.4. Regen Med. 2013. PMID: 23477399 Review. - Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.
Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A. Pascucci L, et al. J Control Release. 2014 Oct 28;192:262-70. doi: 10.1016/j.jconrel.2014.07.042. Epub 2014 Jul 30. J Control Release. 2014. PMID: 25084218 - Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease.
Lai RC, Chen TS, Lim SK. Lai RC, et al. Regen Med. 2011 Jul;6(4):481-92. doi: 10.2217/rme.11.35. Regen Med. 2011. PMID: 21749206 Review. - Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration.
Nakamura Y, Miyaki S, Ishitobi H, Matsuyama S, Nakasa T, Kamei N, Akimoto T, Higashi Y, Ochi M. Nakamura Y, et al. FEBS Lett. 2015 May 8;589(11):1257-65. doi: 10.1016/j.febslet.2015.03.031. Epub 2015 Apr 8. FEBS Lett. 2015. PMID: 25862500
Cited by
- Extracellular Vesicle- and Mitochondria-Based Targeting of Non-Small Cell Lung Cancer Response to Radiation: Challenges and Perspectives.
Leonov S, Dorfman A, Pershikova E, Inyang O, Alhaddad L, Wang Y, Pustovalova M, Merkher Y. Leonov S, et al. Cancers (Basel). 2024 Jun 15;16(12):2235. doi: 10.3390/cancers16122235. Cancers (Basel). 2024. PMID: 38927940 Free PMC article. Review. - Mesenchymal stem cell-derived exosomes: a promising alternative in the therapy of preeclampsia.
Shi H, Yang Z, Cui J, Tao H, Ma R, Zhao Y. Shi H, et al. Stem Cell Res Ther. 2024 Feb 5;15(1):30. doi: 10.1186/s13287-024-03652-0. Stem Cell Res Ther. 2024. PMID: 38317195 Free PMC article. Review. - GMP-compliant manufacturing of biologically active cell-derived vesicles produced by extrusion technology.
Lau HC, Han DW, Park J, Lehner E, Kals C, Arzt C, Bayer E, Auer D, Schally T, Grasmann E, Fang H, Lee JY, Lee HS, Han J, Gimona M, Rohde E, Bae S, Oh SW. Lau HC, et al. J Extracell Biol. 2022 Dec 25;1(12):e70. doi: 10.1002/jex2.70. eCollection 2022 Dec. J Extracell Biol. 2022. PMID: 38938599 Free PMC article. - The Application of MSCs-Derived Extracellular Vesicles in Bone Disorders: Novel Cell-Free Therapeutic Strategy.
Liu S, Xu X, Liang S, Chen Z, Zhang Y, Qian A, Hu L. Liu S, et al. Front Cell Dev Biol. 2020 Jul 22;8:619. doi: 10.3389/fcell.2020.00619. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32793590 Free PMC article. Review. - Regulation of Interferon-β-Modified Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Proliferation and Apoptosis of Prostate Cancer Cells.
Yuan H, Li S, Zhao Z, Wang Y. Yuan H, et al. Organogenesis. 2023 Dec 31;19(1):2285836. doi: 10.1080/15476278.2023.2285836. Epub 2023 Nov 30. Organogenesis. 2023. PMID: 38031805 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources